Davis Gregory D's Form 4 filing
Sangamo Therapeutics, Inc (SGMOQ) · filed Apr 23, 2026
- Accession no.
- 0002041855-26-000008
- Filed
- Apr 23, 2026, 4:07 PM ET
- Trade date
- Apr 22, 2026
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction. Open-market sales total $17.7K. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Davis Gregory DCIK 0002041855 | Officer (Head of Research & Technology) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 22, 2026 | Common Stock | SSaleDisposed | −69,827 | $0.2534F1 | −$17,694.16 | 115,284 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $0.2533 to $0.2568, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price.
Referenced by the price of 1 transaction in Table I.